- A Case of Hepatocellular Carcinoma with Pulmonary Metastasis Who Showed Complete Response by Cytotoxic Chemotherapy after Sorafenib Failure
-
Hwa-Sun Park, Jae Young Jang, Min Young Baek, Yong Kwon Kim, Hyun Jin Youn, Su Young Back, Soung Won Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
-
J Liver Cancer. 2017;17(1):72-76. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.72
-
-
Abstract
PDF
- Hepatocellular carcinoma (HCC) is the 2nd most common cause of cancer related death
in Korea and well-known malignancy with poor prognosis. Sorafenib is the first-line
molecular targeted agent in patients with extra-hepatic spread of HCC. However, complete
response is extremely rare in patients treated with sorafenib and the disease control rate
is only 43%. We report a 53-year-old man with advanced HCC with pulmonary metastasis
who showed complete response by cytotoxic chemotherapy with doxorubicin and
cisplatin with relatively tolerable adverse effects after failure of treatment with sorafenib.
- A Case of Surgical Resection in Hepatocellular Carcinoma with Pulmonary Metastasis
-
Woo Jin Jung, Jae Young Jang, Jun Seok Park, Hee Jeong Lee, Young Kyu Cho, Soung Won Jeong, Sae Hwan Lee, Snag Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
-
J Liver Cancer. 2016;16(2):145-150. Published online September 30, 2016
-
DOI: https://doi.org/10.17998/jlc.16.2.145
-
-
Abstract
PDF
- Hepatocellular carcinoma (HCC) is well known malignancy with poor prognosis, even after
resection of the primary tumor. Sorafenib is the first-line treatment in advanced HCC, but the
disease control rate of sorafenib is only 43%. Pulmonary metastasectomy in patients with
pulmonary metastasis from HCC has been reported to increase long-term survival compared
with systemic chemotherapy. Video-assisted thoracic surgery is considered a reliable
approach to the diagnosis and treatment of pulmonary diseases with low complication
rate. Pulmonary metastasectomy is not universally accepted because of frequent local
recurrence, an uncontrollable primary tumor, and frequent multiple pulmonary metastases
in HCC, but outcome of pulmonary metastasectomy and adjuvant sorafenib therapy has
not been studied. We experienced a patient who had advanced HCC with pulmonary
oligometastasis and received surgical resection of the metastatic pulmonary nodule and
sorafenib chemotherapy. In advanced HCC with pulmonary oligometastasis, surgical
resection of pulmonary metastasis and sorafenib chemotherapy should be considered.
|